| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00752219 | Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections | PHASE2 | COMPLETED | 204 | — | — | Mar 31, 2009 | Dec 31, 2009 | Jul 3, 2018 | 45 | United States, Bulgaria +6 |
Clinical response was defined as complete resolution or significant improvement of signs and symptoms of the index infection. No further antimicrobial therapy or surgical or radiological intervention was required. This clinical response was measured in participants who were microbiologically evaluable (ME) at baseline.
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 6 weeks after last dose of study treatment that were absent before treatment or that worsened relative to pretreatment state.
| Arm | Type | Description |
|---|---|---|
| NXL104/CAZ/MTZ | EXPERIMENTAL | NXL104/ceftazidime + metronidazole |
| Meropenem | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ceftazidime/NXL104 + metronidazole | DRUG | IV TID |
| meropenem | DRUG | IV TID |
Inclusion Criteria: * complicated intra-abdominal infections Exclusion Criteria: * infections limited to hollow viscus * ischemic bowel disease without perforation * acute suppurative cholangitis * acute necrotizing pancreatitis * pts to undergo stated abdominal repair, open abdomen technique or ...